Related Experiment Video
Updated: May 9, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Multiple sclerosis: identification of temporal changes in brain lesions with computer-assisted detection software.
M Bilello1, M Arkuszewski, P Nucifora
1Department of Radiology, Division of Neuroradiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
The Neuroradiology Journal
|July 18, 2013
Summary
Computer-assisted detection (CAD) software improves the detection of brain lesion changes in multiple sclerosis (MS) patients. This tool enhances diagnostic accuracy and efficiency for neuroradiologists monitoring MS progression.
Area of Science:
- Neurology
- Medical Imaging
- Computer Science
Background:
- Multiple sclerosis (MS) is a chronic, progressive neurological disease.
- Serial magnetic resonance imaging (MRI) is crucial for monitoring MS.
- Tracking changes in brain lesions is essential for patient management.
Purpose of the Study:
- To evaluate the performance of a developed computer-assisted detection (CAD) software for tracking temporal changes in MS brain lesions.
- To compare the diagnostic accuracy and interpretation time of CAD-assisted versus routine clinical MRI interpretation in MS patients.
Main Methods:
- Developed a CAD software pipeline to track T2-bright MS lesions on 3D FLAIR MR sequences.
- Compared CAD-assisted interpretation with routine clinical interpretation using 98 paired MR examinations from 88 MS patients.
- Established ground truth through a three-expert panel consensus.
Main Results:
- CAD interpretation demonstrated higher case-wise sensitivity (87%) compared to clinical reports (77%).
- Lesion-wise analysis showed improved sensitivity of CAD over routine interpretation by 40%-48%.
- Mean interpretation time for CAD-assisted analysis was 2.7 minutes.
Conclusions:
- The developed CAD software shows potential for integration into neuroradiology workflows for detecting MS lesion changes.
- Automated quantification of MS lesion load changes could benefit clinical research, including drug trials.

